| 1 |
乙型肝炎病毒耐药专家委员会. 乙型肝炎病毒耐药专家共识: 2009年更新[J]. 中华实验和临床感染病杂志:电子版,2009,3(1):72-79.
|
| 2 |
乙型肝炎病毒耐药讨论专家委员会. 核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J]. 中华实验和临床感染病杂志:电子版,2012,6(6):116-123.
|
| 3 |
Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ,2008,336(7650):924.
|
| 4 |
Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization[J]. Ann Intern Med,2003,139(6):493-498.
|
| 5 |
中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J/CD]. 中国肝脏病杂志:电子版,2015,7(3):1-18.
|
| 6 |
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology,2009,50(3):661-662.
|
| 7 |
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
|
| 8 |
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. European Association For The Study Of The Liver[J]. J Hepatol,2012,57(1):167-185.
|
| 9 |
Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy[J]. J Hepatol,2008,48 (Suppl 1):S2-S19.
|
| 10 |
Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C[J]. Gastroenterology,2012,142(6):1303-1313.
|
| 11 |
Wang F, Wang H, Shen H, et al. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues[J]. Clin Ther,2009,31(2):360-366.
|
| 12 |
吴珍萍，韩涛，高英堂, 等. 拉米夫定耐药后序贯治疗中HBV准种的演变[J]. 世界华人消化杂志,2010,18(8):779-785.
|
| 13 |
刘霖，汤影子，李俊刚, 等. 拉米夫定与恩替卡韦序贯治疗中的乙型肝炎病毒准种动力学[J]. 中华肝脏病杂志,2010,18(6):423-427.
|
| 14 |
Chen L, Zhang Q, Yu DM, et al. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy[J]. J Hepatol,2009,50(5):895-905.
|
| 15 |
Liu F, Chen L, Yu DM. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy[J]. Gut,2011,60(9):1269-1277.
|
| 16 |
Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients[J]. Gastroenterology,2007,133(5):1445-1451.
|
| 17 |
Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol,2007,5(8):890-897.
|
| 18 |
替比夫定中国路线图专家讨论组. 替比夫定治疗慢性乙型肝炎中国路线图[J]. 中华肝脏病杂志,2008,16(5):323-325.
|
| 19 |
Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future[J]. Antivir Ther,2009,14(1):13-22.
|
| 20 |
Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med,2007,357(25):2576-2588.
|
| 21 |
Chae HB, Kim MJ, Seo EG. High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B[J]. Korean J Hepatol,2012,18(1):75-83.
|
| 22 |
Liang LB, Chen LL, Chen EQ, et al. Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy[J]. Ther Clin Risk Manag,2015,11:417-423.
|
| 23 |
Baran B, Soyer OM, Ormeci AC, et al. Efficacy of tenofovir in patients with lamivudine failure is not different from that in nucleoside/nucleotide analogue-naïve patients with chronic hepatitis B[J]. Antimicrob Agents Chemother,2013,57(4):1790-1796.
|
| 24 |
Park JH, Jung SW, Park NH, et al. Efficacy of tenofovir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients with failure of lamivudine and adefovir combination[J]. Clin Ther,2015,37(7):1433-1442.
|
| 25 |
Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy[J]. Hepatology,2009 49(5):1503-1514.
|
| 26 |
Nguyen NH, Trinh HN, Nguyen TT, et al. Safety and efficacy of entecavir in adefovir-experienced patients[J]. J Gastroenterol Hepatol,2015,30(1):43-50.
|
| 27 |
李兰娟，侯金林. 核苷(酸)类药物联合治疗慢性乙型肝炎专家建议[J]. 中华临床感染病杂志,2011,4(2):65-68.
|
| 28 |
Hou J, Sun J, Xie Q, et al. Virological breakthrough and genotypic resistance in a roadmized, controlled, study on telbivudine treatment applying roadmap concept in CHB: W76 interim analysis of effort study[J]. J Hepatol,2012,56(Supp1 2):S203-S204.
|
| 29 |
Piratvisuth T, Komolmit P, Tanwandee T, et al. 1-year results of telbivudine roadmap study demonstrated maximizing antiviral efficacy and minimizing resistance in HBeAg positive chronic hepatitis B patients[C]. 2011. EASL.
|
| 30 |
Chen EQ, Zhou TY, Bai L, et al. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir[J]. Antivir Ther,2012,17(6):973-979.
|
| 31 |
Levrero M, Cimino L, Lampertico P, et al. OptiB--a multicenter prospective open label study on tenofovir for chronic hepatitis B patients with suboptimal response to adefovir or ADV/LAM treatment[C]. 2011. EASL.
|
| 32 |
Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med,2006,354(10):1001-1010.
|
| 33 |
Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med,2008,359(23):2442-2455.
|
| 34 |
Lok AS, Trinh H, Carosi G, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir[J]. J Clin Gastroenterol,2016,50(4):338-344.
|
| 35 |
Peng J, Cao J, Yu T, et al. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B[J]. Saudi J Gastroenterol,2015,21(4):245-253.
|
| 36 |
Lu J, Li J, Liu Y, et al. Study on Post-treatment relapse in HBeAg positive CHB patients[J]. PLoS One,10(11):e0141072.
|
| 37 |
胡伯斌，江建宁，付嘉鑫, 等. HBeAg阳性慢性乙型肝炎患者经核苷和核苷酸类药物治疗达标停药后复发的相关因素[J]. 临床肝胆病杂志,2016,32(5):885-889.
|
| 38 |
Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J]. Gastroenterology,2010,139(2):491-498.
|
| 39 |
van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase[J]. Gut,2003,52(3):420-424.
|
| 40 |
Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea[J]. Hepatology,2000,32(4 Pt 1):803-806.
|
| 41 |
Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B[J]. Hepatology,2003,37(4):748-755.
|
| 42 |
Yoon SK, Jang JW, Kim CW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion[J]. Intervirology,2005,48(6):341-349.
|
| 43 |
Shin JW, Park NH, Park JH, et al. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B[J]. J Viral Hepat,2005,12(4):393-397.
|
| 44 |
Fung J, Lai CL, Yuen J, et al. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 years[J]. Hepatology,2011,53(4):1148-1153.
|
| 45 |
Wang Z, Wu XL, Zeng WZ, et al. Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment[J]. Virol J,2011,8:388.
|
| 46 |
万谟彬，翁心华. 拉米夫定优化治疗慢性乙型肝炎专家共识[J]. 中华传染病杂志,2012,30(7):387-390.
|